[go: up one dir, main page]

CO2020006257A2 - Composiciones farmacéuticas inyectables de isoxazolina y usos de las mismas contra infestación parasitaria - Google Patents

Composiciones farmacéuticas inyectables de isoxazolina y usos de las mismas contra infestación parasitaria

Info

Publication number
CO2020006257A2
CO2020006257A2 CONC2020/0006257A CO2020006257A CO2020006257A2 CO 2020006257 A2 CO2020006257 A2 CO 2020006257A2 CO 2020006257 A CO2020006257 A CO 2020006257A CO 2020006257 A2 CO2020006257 A2 CO 2020006257A2
Authority
CO
Colombia
Prior art keywords
isoxazoline
injectable pharmaceutical
pharmaceutical compositions
parasitic infestation
against parasitic
Prior art date
Application number
CONC2020/0006257A
Other languages
English (en)
Inventor
Keith A Freehauf
Brian Carrillo
Original Assignee
Intervet Int Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=74717047&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO2020006257(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Intervet Int Bv filed Critical Intervet Int Bv
Publication of CO2020006257A2 publication Critical patent/CO2020006257A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/04—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/72—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with nitrogen atoms and oxygen or sulfur atoms as ring hetero atoms
    • A01N43/80—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with nitrogen atoms and oxygen or sulfur atoms as ring hetero atoms five-membered rings with one nitrogen atom and either one oxygen atom or one sulfur atom in positions 1,2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/14—Ectoparasiticides, e.g. scabicides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Agronomy & Crop Science (AREA)
  • Pest Control & Pesticides (AREA)
  • Plant Pathology (AREA)
  • Dentistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicinal Preparation (AREA)

Abstract

Una composición farmacéutica inyectable que comprende un compuesto de isoxazolina de la Fórmula (I) Fórmula (I) o una sal o N-óxido del mismo en donde el compuesto de isoxazolina tiene un tamaño de partícula de 25 micras aproximadamente a 250 micras aproximadamente y un método para prevenir o tratar una infestación de parásitos mediante el uso del mismo.
CONC2020/0006257A 2017-11-07 2020-05-22 Composiciones farmacéuticas inyectables de isoxazolina y usos de las mismas contra infestación parasitaria CO2020006257A2 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762582381P 2017-11-07 2017-11-07
US201762608904P 2017-12-21 2017-12-21
PCT/EP2018/080226 WO2019091936A1 (en) 2017-11-07 2018-11-06 Injectable isoxazoline pharmaceutical compositions and their use against parasite infestation

Publications (1)

Publication Number Publication Date
CO2020006257A2 true CO2020006257A2 (es) 2020-05-29

Family

ID=74717047

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2020/0006257A CO2020006257A2 (es) 2017-11-07 2020-05-22 Composiciones farmacéuticas inyectables de isoxazolina y usos de las mismas contra infestación parasitaria

Country Status (19)

Country Link
US (1) US20210177808A1 (es)
EP (2) EP3707128B1 (es)
JP (1) JP7269927B2 (es)
KR (2) KR102606187B1 (es)
CN (2) CN118576555A (es)
AU (2) AU2018363682B2 (es)
BR (2) BR112020008853A2 (es)
CA (1) CA3081646C (es)
CL (1) CL2020001173A1 (es)
CO (1) CO2020006257A2 (es)
DK (1) DK3707128T3 (es)
ES (1) ES2970570T3 (es)
FI (1) FI3707128T3 (es)
IL (1) IL274065B2 (es)
MX (1) MX2020004694A (es)
PE (1) PE20201150A1 (es)
PH (1) PH12020550555B1 (es)
UA (1) UA127456C2 (es)
WO (1) WO2019091936A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020004693A (es) 2017-11-07 2020-08-20 Intervet Int Bv Proceso para preparar partículas de isoxazolina de gran tamaño.
EP3934618A1 (en) * 2019-03-06 2022-01-12 Zoetis Services LLC Ready-to-use injectable formulations
US20220354828A1 (en) * 2019-10-01 2022-11-10 Shilpa Medicare Ltd Controlled release injectable ondansetron formulations
US20230310386A1 (en) * 2020-05-20 2023-10-05 Intervet Inc. Injectable pharmaceutical compositions and uses thereof
CN114306231B (zh) * 2021-12-29 2023-03-24 天津市中升挑战生物科技有限公司 一种氟雷拉纳杀虫剂及其制备方法和应用
WO2025034192A1 (en) 2023-08-07 2025-02-13 Yuriy Synytsya A water-soluble afoxolaner complex, a method for producing thereof and veterinary antiparasitic drugs comprising the same

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3740421A (en) 1966-09-19 1973-06-19 Basf Wyandotte Corp Polyoxyethylene-polyoxypropylene aqueous gels
KR101197482B1 (ko) 2004-03-05 2012-11-09 닛산 가가쿠 고교 가부시키 가이샤 이속사졸린 치환 벤즈아미드 화합물 및 유해생물 방제제
TW200803740A (en) 2005-12-16 2008-01-16 Du Pont 5-aryl isoxazolines for controlling invertebrate pests
TWI412322B (zh) 2005-12-30 2013-10-21 Du Pont 控制無脊椎害蟲之異唑啉
NZ581452A (en) * 2007-06-07 2012-11-30 Kyalin Bioscience Inc Intranasal carbetocin formulations and methods for the treatment of autism
TWI430995B (zh) 2007-06-26 2014-03-21 Du Pont 萘異唑啉無脊椎有害動物控制劑
PL2957284T3 (pl) 2007-06-27 2018-08-31 E. I. Du Pont De Nemours And Company Sposób zwalczania szkodników zwierzęcych
TWI556741B (zh) 2007-08-17 2016-11-11 英特威特國際股份有限公司 異唑啉組成物及其作為抗寄生蟲藥上的應用
WO2009063910A1 (ja) 2007-11-12 2009-05-22 Nissan Chemical Industries, Ltd. 光学活性イソキサゾリン化合物の触媒的不斉合成方法
TWI411395B (zh) 2007-12-24 2013-10-11 Syngenta Participations Ag 殺蟲化合物
US8377942B2 (en) 2008-12-18 2013-02-19 Novartis Ag Isoxazolines derivatives and their use as pesticide
BRPI0923009B1 (pt) 2008-12-19 2018-07-17 Elanco Tiergesundheit Ag compostos de isoxazolina, composição para o controle de parasitas e uso de compostos de isoxazolina para o preparo de composição para o controle de parasitas
BRPI1011453A2 (pt) * 2009-06-24 2016-03-15 Msd Oss Bv formulacao, forma de dosagem de um medicamento, e, sal de hemipamoato de asenapina
JP5679102B2 (ja) 2009-08-03 2015-03-04 日産化学工業株式会社 ジヒドロイソキサゾール置換安息香酸化合物の光学活性体とジアステレオマー塩及びその製造方法
TWI487486B (zh) 2009-12-01 2015-06-11 Syngenta Participations Ag 以異唑啉衍生物為主之殺蟲化合物
EP3078664B1 (en) 2009-12-17 2019-02-20 Merial Inc. Antiparasitic dihydroazole compositions
EP2556060A1 (en) 2010-04-08 2013-02-13 Ah Usa 42 Llc Substituted 3,5- diphenyl-isoxazoline derivatives as insecticides and acaricides
NZ603584A (en) * 2010-05-27 2015-02-27 Du Pont Crystalline form of 4-[5-[3-chloro-5-(trifluoromethyl)phenyl]-4,5-dihydro-5-(trifluoromethyl)-3-isoxazolyl]-n-[2-oxo-2-[(2,2,2-trifluoroethyl)amino]ethyl]-1-naphthalenecarboxamide
CA2924537C (en) 2013-09-30 2018-01-16 Todd P. Foster Long-acting spiro-isoxazoline formulations
ES2971061T3 (es) * 2013-12-20 2024-06-03 Intervet Int Bv Composiciones de isoxazolina y uso de las mismas en la prevención o el tratamiento de infestaciones parasitarias en animales
UY36570A (es) * 2015-02-26 2016-10-31 Merial Inc Formulaciones inyectables de acción prolongada que comprenden un agente activo isoxazolina, métodos y usos de las mismas
CA2981797C (en) 2015-04-08 2023-11-21 Merial, Inc. Extended release injectable formulations comprising an isoxazoline active agent, methods and uses thereof
EP3393455B1 (en) * 2015-12-22 2021-07-21 Intervet International B.V. Injectable formulation of a macrocyclic lactone and levamisole
UY37137A (es) 2016-02-24 2017-09-29 Merial Inc Compuestos antiparasitarios de isoxazolina, formulaciones inyectables de acción prolongada que los comprenden, métodos y usos de los mismos
MX2020004693A (es) * 2017-11-07 2020-08-20 Intervet Int Bv Proceso para preparar partículas de isoxazolina de gran tamaño.
JP7558197B2 (ja) * 2019-05-03 2024-09-30 インターベット インターナショナル ベー． フェー． 注射可能な医薬組成物及びその使用

Also Published As

Publication number Publication date
FI3707128T3 (fi) 2024-03-01
CA3081646C (en) 2024-03-19
CN111295376B (zh) 2024-05-24
US20210177808A1 (en) 2021-06-17
EP4316522A2 (en) 2024-02-07
EP4316522A3 (en) 2024-04-03
RU2020117596A (ru) 2021-12-08
KR102606187B1 (ko) 2023-11-23
PH12020550555A1 (en) 2021-03-08
AU2024201169A1 (en) 2024-03-14
PH12020550555B1 (en) 2024-03-06
NZ764055A (en) 2024-07-05
CN118576555A (zh) 2024-09-03
KR20230161544A (ko) 2023-11-27
IL274065B1 (en) 2023-05-01
PE20201150A1 (es) 2020-10-26
IL274065A (en) 2020-06-30
UA127456C2 (uk) 2023-08-30
CA3081646A1 (en) 2019-05-16
WO2019091936A1 (en) 2019-05-16
MX2020004694A (es) 2020-07-27
DK3707128T3 (da) 2024-03-18
BR122023023401A2 (pt) 2024-02-20
JP7269927B2 (ja) 2023-05-09
CN111295376A (zh) 2020-06-16
EP3707128A1 (en) 2020-09-16
EP3707128B1 (en) 2023-12-20
IL274065B2 (en) 2023-09-01
ES2970570T3 (es) 2024-05-29
KR20200085810A (ko) 2020-07-15
KR102677903B1 (ko) 2024-06-21
CL2020001173A1 (es) 2020-10-23
BR112020008853A2 (pt) 2020-10-13
AU2018363682B2 (en) 2023-11-23
AU2018363682A1 (en) 2020-05-07
JP2021501758A (ja) 2021-01-21

Similar Documents

Publication Publication Date Title
CO2020006257A2 (es) Composiciones farmacéuticas inyectables de isoxazolina y usos de las mismas contra infestación parasitaria
ECSP17002135A (es) Compuestos antiproliferativos y métodos de uso de los mismos
PE20190709A1 (es) Derivado de pirazolopiridinaque tiene el efecto agonista del receptor de glp-1
CO2017006197A2 (es) Composiciones fungicidas
CL2013003287A1 (es) Compuestos derivados de 5-trifluorometil-4,5-dihidro-isoxazol; compuestos intermediarios; procedimiento de preparacion; composiciones farmaceuticas que los comprenden; y uso en el tratamiento de una infestacion de parasitos en animales.
CR20160564A (es) Dinucleótidos cíclicos como moduladores de sting
CU20170077A7 (es) Compuesto derivado de benzamida sustituida con 1,3-tiazol-2-ilo útil para el tratamiento de trastornos neurogénicos, composiciones y combinaciones que lo comprende
CL2018001744A1 (es) Compuestos depsipeptídicos como anthelmínticos
CL2018000688A1 (es) Compuestos heterociclicos que contienen bencilamina y composiciones útiles contra infección por micobacterias
UY37879A (es) Compuestos de bisamida que activan el sarcómero y sus usos
CR20170425A (es) Nuevas proteínas específicas para pioverdina y pioquelina
UY36683A (es) Compuestos depsipeptídicos como anthelmínticos
CL2019001041A1 (es) Compuestos terapéuticos y métodos para utilizarlos.
CO2021014266A2 (es) Composiciones farmacéuticas inyectables y usos de las mismas
CO2019011546A2 (es) Compuestos y métodos para el tratamiento de enfermedades parasitarias
MX381776B (es) Formulacion acuosa que comprende paracetamol e ibuprofeno.
DOP2022000035A (es) Composiciones que comprenden tigolaner para el control de parásitos
AR101581A1 (es) Composición de colutorio
MX2017009849A (es) Composiciones de profármaco de monometilfumarato.
AR101806A1 (es) Derivados de 1-acetil-4-amino-1,2,3,4-tetrahidroquinolina, composición farmacéutica que los comprende y su uso en el tratamiento de afecciones mediadas por un inhibidor de bromodominio
BR112017023164A2 (pt) composto, e, método de prevenir e/ou tratar a esteato-hepatite não alcoólica em um indivíduo em necessidade do mesmo
MX2020004842A (es) Compuestos heterociclicos antiinfecciosos y sus usos.
MX2023014279A (es) Composiciones farmaceuticas inyectables de isoxazolina y su uso contra la infestacion de parasitos.
UY37502A (es) Dinucleótido cíclico
MX2018016339A (es) Compuestos heterociclicos antiinfecciosos y sus usos.